STOCK TITAN

Elanco Animal Health - ELAN STOCK NEWS

Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.

Overview of Elanco Animal Health

Elanco Animal Health is a global pharmaceutical company that specializes in developing, manufacturing, and marketing innovative health solutions for animals. With a rich heritage spanning nearly seven decades, the company is dedicated to its vision of "Food and Companionship Enriching Life." This commitment is achieved by enhancing the health and performance of food animals, extending the quality and longevity of companion animals, and improving food safety through advanced veterinary products.

Business Model and Core Operations

At its core, Elanco operates in two principal business segments: Farm Animal Health and Companion Animal Health. Through an integrated portfolio of products including vaccines, parasiticides, and therapeutic solutions, the company addresses critical animal health issues. The farm animal division emphasizes improving livestock productivity and food safety by offering products that support cattle, sheep, goats, and swine production. The companion animal division focuses on innovative products that help pets live longer, healthier lives by addressing common ailments and diseases through advanced pharmaceutical formulations and targeted therapies.

Global Footprint and Market Presence

Elanco operates on a global scale, reaching over 90 countries and integrating diverse markets across North America, Europe, Asia, and Latin America. Its expansive network of research and manufacturing facilities, combined with the strategic integration of acquired businesses such as Janssen Animal Health, Novartis Animal Health, Boehringer Ingelheim Vetmedica, and Bayer Animal Health, reinforces its position within the competitive landscape of veterinary pharmaceuticals. The company’s robust international presence ensures that it is well positioned to cater to a diverse customer base including farmers, veterinarians, pet owners, and stakeholders in food production chains.

Innovation and Research & Development

Innovation is at the heart of Elanco’s operations. The company invests significantly in research and development to create breakthrough solutions that address both long-standing and emerging animal health challenges. Its R&D efforts not only focus on new product development but also on lifecycle management and the strategic enhancement of existing products. By leveraging advanced veterinary sciences and manufacturing technologies, Elanco continuously improves product efficacy and safety, adhering to stringent quality standards. This sustainable innovation strategy underpins its ability to stay ahead of market dynamics and provides a competitive edge in the transformative field of animal health.

Quality Systems and Regulatory Excellence

Elanco maintains rigorous quality systems that ensure the safety, efficacy, and reliability of its products. The company works closely with regulatory bodies, including the U.S. Food and Drug Administration (FDA) and international counterparts, to comply with evolving industry standards and requirements. Its comprehensive quality control and risk management practices are designed to meet the highest levels of safety and regulatory compliance, which not only protect animal health but also contribute to public health by ensuring food safety.

Corporate Culture and Values

The company is driven by a culture defined by humility, discipline, and active involvement. Elanco empowers its employees to contribute meaningfully to its mission, fostering an environment that emphasizes personal and professional growth. This cultural commitment translates into operations that are both ethical and customer-focused, ensuring that every solution delivered is rooted in a strong sense of purpose and responsibility.

Strategic Integration and Acquisitions

Elanco’s history of strategic acquisitions has played a pivotal role in shaping its modern-day operations. By integrating legacy businesses from notable pharmaceutical companies, Elanco has broadened its product portfolio and enhanced its technological capabilities. These integrations have facilitated significant scale advantages and allowed the company to offer cohesive and comprehensive solutions across different sectors of animal health. The synergy achieved from these acquisitions not only optimizes production efficiencies but also accelerates product innovation and market responsiveness.

Positioning in a Competitive Landscape

Operating in a highly competitive industry, Elanco differentiates itself through its deep commitment to animal health and relentless focus on research and innovation. The company’s dual focus on both companion and farm animal segments enables it to leverage a diverse portfolio, buffer challenges across markets, and address varying customer needs. Its scientific expertise, robust product pipeline, and extensive global distribution network establish the company as a trusted name in animal health solutions.

Enhanced Value for Stakeholders

Elanco’s operations are centered on delivering sustainable value for all its stakeholders. Its products provide critical support for food production, contribute to animal welfare, and ensure safe and effective treatments for companion animals. By integrating quality systems, scientific innovation, and a responsible corporate culture, Elanco continues to drive improvements in animal health while playing a key role in enhancing overall public health and wellbeing.

Conclusion

In summary, Elanco Animal Health represents an institution deeply committed to advancing animal health through innovative veterinary pharmaceuticals and products. With a strong global presence, a diverse and integrated product portfolio, and an unwavering dedication to quality and innovation, Elanco is well positioned to continue its mission of enriching life by advancing the health of both food animals and pets. The company’s strategic approach, rigorous quality control, and sustainable innovation make it a pivotal player in the animal health industry, offering valuable insights and reliable solutions to customers worldwide.

  • Key Business Segments: Farm Animal Health, Companion Animal Health
  • Innovation Focus: Advanced R&D, breakthrough veterinary pharmaceuticals
  • Global Reach: Operations across 90+ countries
  • Strategic Integration: Incorporation of legacy companies to bolster product portfolio
  • Regulatory Excellence: Compliance with rigorous quality and safety standards
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) reported fourth quarter and full year 2023 financial results, with revenue of $1,035 million and $4,417 million respectively. The company announced a strategic restructuring impacting approximately 420 personnel to generate savings and reinvest in value creation opportunities. Full year 2024 guidance includes revenue of $4,450 to $4,540 million and adjusted EBITDA of $960 to $1,010 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Elanco Animal Health Incorporated (ELAN) to participate in upcoming investor conferences, featuring key executives in fireside chats at major events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
-
Rhea-AI Summary
Athian announces the establishment of a livestock carbon insetting marketplace with the first carbon credits verified for sale, in collaboration with Elanco Animal Health. This initiative aims to reduce enteric methane emissions and improve feed utilization, offering dairy farmers the opportunity to monetize their greenhouse gas emission reductions. The marketplace enables companies in the dairy value chain to purchase carbon credits to support their emissions reduction goals, while returning economic value to farmers. Elanco's UpLook tool helps farmers measure and monitor greenhouse gas emissions, further enhancing sustainability efforts. This innovative marketplace addresses the challenge of reducing Scope 3 emissions in the animal protein value chain, providing a significant opportunity for companies to achieve their sustainability goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Rhea-AI Summary
Cattler, an agtech company, has launched an interface with Elanco Animal Health Incorporated as part of their agreement to provide data collaboration for customers participating in Elanco Knowledge Solutions services. This partnership aims to provide Cattler customers with streamlined access to Elanco's data services and products, allowing cattle feeders to optimize their practices and gain actionable insights. The interface will provide global cattle producers with access to Elanco's Benchmark and Experior Data Services, enhancing the producer's experience with the Cattler platform. Elanco's Benchmark program is designed to convert data into information to help cattle feeders identify strengths and opportunities to pursue and measure performance over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its fourth quarter and full year 2023 financial results on February 26, 2024. The company will also conduct a conference call to discuss its performance, which will be accessible to investors, media, and the general public via a live webcast on Elanco's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary
Elanco Animal Health's CEO, Jeff Simmons, discussed the company's pipeline with six potential blockbuster products and the launch of a USDA conditionally-approved therapeutic solution for canine parvovirus on Mad Money. The company also announced a campaign to save 1 million puppies from parvo, aiming to increase education about the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
Rhea-AI Summary
Merck Animal Health, a division of Merck & Co., Inc., is set to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, expanding its aqua portfolio with innovative products and technology solutions. The acquisition includes aqua manufacturing facilities, a research facility, and a portfolio of medicines, vaccines, and supplements for aquatic species. The deal is expected to be completed by mid-year 2024, subject to regulatory approvals and customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
-
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) announced the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, reinforcing its focus on pet health and livestock sustainability. The transaction will enable Elanco to accelerate debt paydown by $1.05B to $1.1B, with net debt to adjusted EBITDA expected in the high-3x to low-4x range by the end of 2025. The aqua business generated an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
-
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) has launched a multi-year campaign to save 1 million puppies from deadly canine parvovirus. The 'Defend Puppies. Defeat Parvo.' mission aims to conquer a virus with a 91% mortality rate, affecting an estimated 900 dogs daily in the U.S. Elanco seeks to increase education and awareness to protect puppies from this highly contagious disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
none
Rhea-AI Summary
The 2024 Feather in Her Cap awards ceremony honored 11 women for their outstanding career achievements in Animal Health, including Andrea J. Gonzales, Ph.D., of Zoetis, Inc. (NYSE: ZTS), and Katharina Bohnenblust, Ph.D., of Elanco Animal Health (NYSE: ELAN). Dr. Gonzales, Vice President of Global Companion Animal Therapeutics at Zoetis, was recognized for her leadership and contributions to the industry, while Dr. Bohnenblust received the 2024 High Flyer award for her accomplishments in pharmaceutical development. The awards aim to inspire the next generation of industry leaders and recognize women's achievements in Animal Health. Dr. Gonzales' passion for building an innovative R&D pipeline of animal health therapeutics and her commitment to mentoring women in the industry were highlighted, and she chose Cheff Therapeutic Riding Center in Kalamazoo, Michigan, as the recipient of a $5,000 charitable donation. Dr. Bohnenblust, who serves as a mentor for young female scientists, developed the new Elanco JAK-inhibitor formulation and manufacturing process. The Feather in Her Cap Association will reopen the nomination process in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none

FAQ

What is the current stock price of Elanco Animal Health (ELAN)?

The current stock price of Elanco Animal Health (ELAN) is $8.48 as of April 21, 2025.

What is the market cap of Elanco Animal Health (ELAN)?

The market cap of Elanco Animal Health (ELAN) is approximately 4.3B.

What is the core mission of Elanco Animal Health?

Elanco’s mission is to enrich life through enhancing animal health, focusing on both food animals and companion pets by delivering safe, innovative, and effective veterinary solutions.

Which business segments does Elanco operate in?

Elanco operates predominantly in the farm animal health and companion animal health segments, providing targeted products such as vaccines, parasiticides, and therapeutic treatments.

How does Elanco generate revenue?

Revenue is generated through the development, manufacturing, and marketing of a broad portfolio of veterinary pharmaceutical products across global markets, catering to both food animal and pet health needs.

What distinguishes Elanco from other companies in the animal health industry?

Elanco’s differentiation lies in its strong focus on innovation, extensive R&D capabilities, strategic global acquisitions, and its commitment to stringent quality and regulatory standards.

How does Elanco ensure the quality and safety of its products?

The company maintains rigorous quality systems, collaborates with global regulatory bodies, and incorporates comprehensive risk management practices to ensure their products are safe, effective, and compliant with industry standards.

What role do strategic acquisitions play in Elanco’s business model?

Strategic acquisitions have expanded Elanco’s product portfolio and technological capabilities, allowing the company to integrate legacy businesses and leverage synergies to drive innovation and market reach.

In which regions does Elanco operate?

Elanco has a significant global footprint, operating in over 90 countries across North America, Europe, Asia, and Latin America, serving a diverse customer base including farmers, veterinarians, and pet owners.

How does Elanco contribute to food safety?

By enhancing the health and performance of food animals through its innovative products, Elanco helps ensure a reliable, safe, and abundant food supply, which is a critical component of its overall mission.
Elanco Animal Health

NYSE:ELAN

ELAN Rankings

ELAN Stock Data

4.31B
491.00M
0.88%
100.87%
2.92%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GREENFIELD